Floatz logo

Dipeptiven

Gastric Cancer

Jagiellonian UniversityPhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

283 Active assets in the Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB
Cyclophosphamide
Vall d'Hebron Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Dipeptiven is also rated in:

ComaDormant
BB
Indicative ·
69 / 100
View asset →
traumatic brain injuryDormant
B
Indicative ·
62 / 100
View asset →
pancreatic neoplasmDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →